Cargando…

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients

To our knowledge, very few data about the role of Topoisomerase IIα (TOPO-IIα), an enzyme involved in critical steps of tumour cell proliferation and chemoresistance are currently available in ovarian cancer patients. The aim of this study was to investigate the prognostic value of TOPO-IIα expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrandina, G, Petrillo, M, Carbone, A, Zannoni, G, Martinelli, E, Prisco, M, Pignata, S, Breda, E, Savarese, A, Scambia, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441958/ https://www.ncbi.nlm.nih.gov/pubmed/18506140 http://dx.doi.org/10.1038/sj.bjc.6604410

Ejemplares similares

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
por: Ferrandina, G, et al.
Publicado: (2005)

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
por: Pignata, S, et al.
Publicado: (2007)

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
por: D'Agostino, G, et al.
Publicado: (2003)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006)

Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial
por: Ferrandina, G, et al.
Publicado: (2009)

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2015)

Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome.
por: Ferrandina, G., et al.
Publicado: (1998)

Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer
por: Petrillo, Marco, et al.
Publicado: (2015)

Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary
por: Mangili, G, et al.
Publicado: (2013)

Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Prognostic significance of ras/p21 alterations in human ovarian cancer.
por: Scambia, G., et al.
Publicado: (1997)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

Prognostic relevance of topoisomerase II α and minichromosome maintenance protein 6 expression in colorectal cancer
por: Hendricks, A., et al.
Publicado: (2019)

Examining the Impact of Antimicrobial Fluoroquinolones on Human DNA Topoisomerase IIα and IIβ
por: Fief, Cole A., et al.
Publicado: (2019)

Detection of the Epstein-Barr Virus and DNA-Topoisomerase II-α in Recurrent and Nonrecurrent Giant Cell Lesion of the Jawbones
por: Zyada, Manal M., et al.
Publicado: (2013)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

Natural Products as Topoisomerase II Poisons: Effects of Thymoquinone on DNA Cleavage Mediated by Human Topoisomerase IIα
por: Ashley, Rachel E., et al.
Publicado: (2014)

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
por: Adamo, V, et al.
Publicado: (2008)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer
por: MacGrogan, G, et al.
Publicado: (2003)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

Femur metastasis in carcinoma of the uterine cervix: a rare entity
por: Corrado, Giacomo, et al.
Publicado: (2009)

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.
por: Scambia, G., et al.
Publicado: (1995)

DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma
por: Cao, Yi, et al.
Publicado: (2017)

Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor.
por: Scambia, G., et al.
Publicado: (1991)

Exploration of the Role of the C-Terminal Domain of Human DNA Topoisomerase IIα in Catalytic Activity
por: Dougherty, Ashley C., et al.
Publicado: (2021)

Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells.
por: Scambia, G., et al.
Publicado: (1990)

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
por: Legge, Francesco, et al.
Publicado: (2011)

Differential expression of topoisomerase IIα protein in salivary gland carcinomas: histogenetic and prognostic implications
por: Maruya, Shin-ichiro, et al.
Publicado: (2009)

A role for topoisomerase IIα in the formation of radiation-induced chromatid breaks
por: Terry, S Y A, et al.
Publicado: (2008)

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
por: Perrone, Francesco, et al.
Publicado: (2016)

Adrenomedullin in Ovarian Cancer: Foe In Vitro and Friend In Vivo?
por: Baranello, Cinzia, et al.
Publicado: (2012)

hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
por: Ercoli, A, et al.
Publicado: (1999)

The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells
por: Farr, Christine J., et al.
Publicado: (2014)

MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ug1t0lv2b6efe7l7a8ta6f25il